Clinical trial
Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy
NCT00210119 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy
- Lead sponsor
- Institut Bergonié
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 12, 2006
- Completion date
- March 31, 2009
- Enrollment
- 19 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
myeloid leukemia, chronic